Antibody Deglycosylation Service

At present, antibody deglycosylation is being extensively studied. Understanding the function of glycosaminoglycans can help us deeply study immunotherapy. CD BioGlyco has developed advanced Antibody Glycoengineering technologies and analysis tools to help customers study antibody deglycosylation systematically.

Deglycosylated Antibodies for Therapeutics

Immunotherapy is one of the most encouraging strategies for cancer treatment, and the most common immunotherapy strategy involves the interruption of the interaction between immune checkpoints expressed on tumors and immune cells, which blocks the immune escape of tumor cells to some extent. The structure and function of monoclonal antibodies have become key research points in tumor therapy.

If a lower propensity to activate inflammatory cascades is desirable deglycosylated antibodies may be good candidates for therapeutics because the removal of glycan reduces the IgG interactions with Fc receptors. Deglycosylated antibodies have been of interest to treat autoimmune disorders and to suppress immune complex-mediated inflammation in a mouse arthritis model by disrupting Fc-Fc interactions while maintaining intact antigen-antibody binding and complement binding.

Antibody deglycosylation has been studied by EndoS (endo-β-N-acetylglucosaminidase) hydrolysis. EndoS is capable of cleaving glycans in the crystallizable fragment (Fc) domain of IgG molecules. This digestion significantly reduces the binding of immune system cell receptors to IgG.

Fig.1 Deglycosylation of IgG Fc by EndoS. (Crispin, 2013)

Antibody Deglycosylation Service at CD BioGlyco

Deglycosylation of antibodies can significantly alter their intrinsic properties and stability, creating challenges for downstream process development. CD BioGlyco provides a fast and efficient technique to remove conserved glycans to eliminate the function of Fc in therapeutic monoclonal antibodies. This facilitates the study of the action mode of IgG.

Applications

• Deglycosylation reduces IgG complement-dependent and antibody-dependent cell-mediated cytotoxicity with a reduction in antigen binding, giving it therapeutic potential
• Deglycosylation results in a more flexible Fc structure within IgG1, allowing a greater understanding of antibody structure
• Deglycosylated IgG has a dominant suppressive effect on inflammation
• Simplify the complex and tedious process of analyzing glycans

Advantages of Us

• Many years of experience in antibody deglycosylation
• Different experimental programs can be selected according to every special need
• A comprehensive and advanced Glycoengineering Platform
• Experienced and well-trained technicians
• Customized service to ensure your flexible choice in an efficient manner

Our team of scientists has many years of experience in antibody deglycosylation. With our advanced Glycoengineering Platform, CD BioGlyco provides customers with strong support for antibody deglycosylation. For more detailed information and quote, please feel free to contact us for deep communication.

Reference:

1. Crispin, M. Therapeutic potential of deglycosylated antibodies. Proceedings of the National Academy of Sciences. 2013, 110(25): 10059-10060.